However, limited research on the roles of anlotinib and anti-PD-L1/anti-PD-1 antibody (aPD-L1/aPD-1) within the ovarian cancer tumor microenvironment (TME) has left their clinical efficacy and underlying mechanisms unclear, hindering broader clinical application and regulatory approval. The gene discussed is CD274; the disease is neoplasm.